In this Section |
268393 Prevalence of physical pain and associated mental health and prescription drug abuse among injection drug users in San FranciscoTuesday, October 30, 2012
Little information exists on the daily experiences of pain among street-level injection drug users. The data reported herein are drawn from an ongoing community-based survey among street-level injection drug users in San Francisco. To date, 143 clinical assessments have been conducted, with sample characteristics as follows: 76% male, median age 35 (sd 14.5 years), and 39% white. Over 56% of the sample reported any physical pain in prior day. The overall pain rating (0-10) was in the moderate range (mean=5.4, sd=2.5). The levels of pain over the day were quite variable, ranging from 7.3 (range 0-10, sd=2.3) at its worst to 2.98 (sd=2.5) at its least. No significant differences were observed in non-medical prescription pain reliever use in the past 6 months (59% among those with pain versus 58% among those with no pain). However, those with current pain had more extensive histories of nonmedical opioid use, using on average of 87 days in the prior 6 months compared to 51 days for those with no pain (p<.001), greater use of more potent Schedule II opioids, and were less likely to tamper as a means of ingestion. High levels of physical pain were associated with greater mental health problems. No differences in health care utilization were observed between those with and without pain, indicating high rates of undertreatment. About 12% of the sample was HIV positive, though not associated with pain. The success of public health interventions must consider the role of pain given its prominence in this community.
Learning Areas:
Assessment of individual and community needs for health educationClinical medicine applied in public health Epidemiology Planning of health education strategies, interventions, and programs Public health or related education Public health or related research Learning Objectives: Keywords: Mental Illness, Prescription Drug Use Patterns
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I am the principal investigator on the research presented in this talk. I am the PI or Co-I on over 20 NIH, CDC, and SAMHSA projects funded to examine mental illness and substance abuse. I have also testified before the FDA on prescription drug abuse and serve on the editorial boards of the Journal of Consulting and Clinical Pscyhology and Health Psychology. I also have 50 plus publications and over 100 presentations at professional meetings. I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
Back to: 4368.0: Suicide and substance use: Prevalence, correlates and prevention
|